Structure Therapeutics Inc Topline Results from Aleniglipron Phase 2 ACCESS Program Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Terrence Flynn - Morgan Stanley - Analyst : Hi. Thanks for taking the questions. I guess the first one I had is there were some, reports that the FDA could move to single Phase 3 trial for approval. So just wondering, your perspective on that, Ray, as you think about the scope of the Phase 3 program. Obviously you have some time here, and then the other question. I just can you remind us about the switch study that you're conducting and what you're hoping to show in that it sounds like you're using you know GLP injectable GLP not GLP, GIP but just wanted to confirm some of the the metrics there and what the goal of that study is. Thank you.

Question: Yasmeen Rahimi - Piper Sandler - Analyst : Good morning, team. Congrats to the data and really thorough presentation. I guess team. As we think about 2, starting with 2.5 and then going to 120 and potentially even 240, what do you think, could we achieve the same weight loss magnitude that you guys just shared with us across ACCESS 1 and ACCESS 2? Just wanting to understand. Could we end up at the same weight loss magnitude by just stretching and going slow over a longer durability? And this is specific to the OLE study that's ongoing. So if you could share your thoughts around what we hope to see at week 28 when we get to the 90 milligrams LSEG STREETEVENTS | www.lseg.com | Contact Us consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies. DECEMBER 08, 2025 / 1:30PM, GPCR.OQ - Structure Therapeutics Inc Topline Results from Aleniglipron Phase 2 ACCESS Program dose group, that would be helpful. And then the second one is a clarification. Do you need to see the 2.5 milligrams OLE data before Before you finalize your Phase 3 development and how you're thinking about titration schedule.

Question: David Reisinger - Leerink Partners - Analyst : Thanks very much and let me add my congrats as well to you, Ray, and the team. So, just to follow-up on that last question, could you provide a little bit more color on, the potential for partnering discussions, including, the potential timeline? Obviously there's a lot of data to go through. But any additional color would be helpful and then since others are asking an additional question, I'll ask one more, which is -- could you talk, a little bit more about the use of patient e diaries and contrast that with how competitors have conducted their trials. Thanks so much.

Question: Roger Song - Jeffries - Analyst : Great, and my congratulations. Maybe, at this point a little bit kind of final question. First is, I think you mentioned most of the AE in the first couple of cycles. Can you just give us a little number on the percentage AE in the first eight weeks and 12 weeks because you give us the 2.5% starting dose and then, just try to estimate how much lower the AE for the 2.5 milligram starting dose. And then also, in your ex access to the discontinuation due to AE go up quite a bit compared to excess. Maybe that's due to the small and maybe the open level extension, maybe just give us a little bit, contact there. How should we think about this 29 -- 27.9% versus 11%. Thank you.

Question: Hardik Parikh - JPMorgan Securities LLC - Analyst : Oh sorry, thank you for taking the question. Just one high level one for me, from a competitive positioning perspective, how do you look at this data when you take into context both a lion ahead of you and then also some other oral small molecules in clinical development alongside you? Thank you.

Question: Patrick Dolezal - LifeSci Capital LLC - Analyst : Hi, thanks for taking the question. Are there any learnings on the magnitude of HbA1c changes as it relates to the potential of aleniglipron and type 2 diabetes? I know we're just digesting the topline obesity data here, but would love to sort of hear how your thoughts are progressing as it relates to the potential of enoglyon and follow-on indications. Thanks.

Question: Corinne Johnson - Goldman Sachs Group Inc - Analyst : Thanks, good morning. How many titration schemes do you think based on this data you'd like to take forward into Phase 3? And I'm curious, are you thinking about the study duration that'll be needed to fully elucidate that efficacy profile given sort of the number of steps that might be required to get up to the final dose? Thanks.